Xia-juan J. Huan

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

UBA3 reduction sensitizes cancer cells to NAE inhibitors.

UBA3 reduction sensitizes cancer cells to NAE inhibitors.

Journal: Life science alliance
Published: December 04, 2025

UBE4B modulates BET inhibitor sensitivity via KLHL22-JAK2-PIM1 axis in hepatocellular carcinoma.

UBE4B modulates BET inhibitor sensitivity via KLHL22-JAK2-PIM1 axis in hepatocellular carcinoma.

Journal: Biochemical pharmacology
Published: November 19, 2024

The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression.

The combination of BET and METTL3 inhibitors elicits synergistic antitumor effects in ovarian cancer cells via reducing SP1 and BCL-2 expression.

Journal: Life sciences
Published: October 05, 2024

USP7 V517F mutation as a mechanism of inhibitor resistance.

USP7 V517F mutation as a mechanism of inhibitor resistance.

Journal: Nature communications
Published: August 12, 2024

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors.

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors.

Journal: European journal of medicinal chemistry
Published: April 20, 2024

The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.

The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.

Journal: Biochemical and biophysical research communications
Published: March 12, 2024

Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy.

Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy.

Journal: Biochemical pharmacology
Published: December 28, 2023

Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells.

Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells.

Journal: Life sciences
Published: July 07, 2023

Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats.

Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats.

Journal: Cancer chemotherapy and pharmacology
Published: July 17, 2022

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.

Journal: EMBO molecular medicine
Published: April 29, 2022

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.

Journal: Neoplasia (New York, N.Y.)
Published: April 07, 2022

Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].

Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].

Journal: Bioorganic & medicinal chemistry letters
Published: December 16, 2021
Showing 1-12 of 37

Last Updated: 09/26/2026